Santis Health

Supporting engagement on the value in curing type one diabetes across Canada by seeking funding for increased and innovative research.

Recommend the creation of a Patient Ombudsman. Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines. Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB. Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs. Provide input on pharmacare. Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency. Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them. Provide input on a national strategy for drugs for rare diseases. Support input regarding Canada’s pharmaceutical sovereignty. Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones. Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States. Recommend the creation of a Chief Patient Officer. Support input into the consultation on draft guidance on decentralized clinical trials. Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Regulations under the Food and Drugs Act, including the Medical Devices Regulation, with respect to the approval of medical technologies North American Free Trade Agreement (NAFTA), with respect to provisions relating to medical devices and technologies Federal science & technology strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry Federal life sciences strategy with respect to patient safety, managing high-risk drugs, medication errors, healthcare worker safety, infection and disease prevention, antimicrobial resistance, and diagnostic testing. Federal life sciences strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry and accelerating innovation to improve health and economic outcomes. Federal initiatives with respect to the Canadian Life Sciences strategy and intergovernmental policy, funding, legislative, and guideline changes. Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry, and economic development and promotion for the life sciences sector Federal budget with respect to science and technology in the healthcare sector, specifically with respect to medical technology and device innovation and adoption, support and delivery new models of care, equitable healthcare access, and women’s health. Federal budget with respect to public sector investments in long-term care and home care. Discuss policies around anti-microbial resistance, infection prevention and medication errors

Discussions on the restructuring of the Canadian Preventative Health Task Force Communicating with government to increase investments in health research Regulations and guidelines affecting women's health like breast cancer screening, access to innovative technology and precision medicine.

Discussions on the restructuring of the Canadian Preventative Health Task Force Regulations and guidelines affecting women's health like breast cancer screening, access to innovative technology and precision medicine. Communicating with government to increase investments in health research

Advocating for a resilient healthcare system, which includes faster access to health care innovation and technology, as well as better access to data and data sharing to help monitor health outcomes.

Discussion on the health human resource issues facing dermatologists such as shortages, wait times and access to care for patients. Discussion on the use of AI/digital health and how that can help improve the profession and more efficient access to care for patients.

Discussion on the use of AI/digital health and how that can help improve the profession and more efficient access to care for patients. Discussion on the health human resource issues facing dermatologists such as shortages, wait times and access to care for patients.

The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage with government to strengthen the Priority Review of Drug Submissions process. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage with government to strengthen the Priority Review of Drug Submissions process. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Enhancing access to sustainable health human resources (HHR) to better serve rural, remote and Indigenous communities across Canada.

To advocate for future budgetary funding for the Canadian Association for Long Term Care, including funding for health human resources and long-term care infrastructure support, as well as funding and other supports for COVID-19 related challenges. Connect the Canadian Association for Long Term Care with government officials to discuss opportunities to support Canada's health care system and to improve seniors care in Canada.

To highlight the significant challenges presented by Chronic Kidney Disease (CKD) and to initiate efforts to generate heightened awareness and sustained support for the National Chronic Kidney Disease Framework.

Our key priorities focus on addressing the chronic underfunding of community mental health organizations, advocating for long-term, sustainable funding models to ensure their full integration into the health care system, and increasing visibility and awareness of their critical role within government.

Continued support for life sciences funding and the emerging area of stem cell and regenerative medicine research. Lobbying is about building awareness about the field and the strength of talent that works within the field.

Assist the ALS Society with the organization of an advocacy day on parliament hill. Connect the ALS Society of Canada with government officials to discuss opportunities to support Canada's health care system and to improve ALS awareness in Canada.

Supporting engagement on the value in curing type one diabetes across Canada by seeking funding for increased and innovative research.

Grant, Contribution or Other Financial Benefit • To advocate for future budgetary funding for the Canadian Association for Long Term Care, including funding for health human resources and long-term care infrastructure support, as well as funding and other supports for COVID-19 related challenges. Policies or Program • Connect with government officials to discuss opportunities to support Canada's health care system and to improve seniors care in Canada.

Policies or Program • Connect with government officials to discuss opportunities to support Canada's health care system and to improve seniors care in Canada. Grant, Contribution or Other Financial Benefit • To advocate for future budgetary funding for the Canadian Association for Long Term Care, including funding for health human resources and long-term care infrastructure support, as well as funding and other supports for COVID-19 related challenges.

Support Canada's health research sector and the critical role of neuroscience, ensuring that existing investments in talent, infrastructure, and equipment deliver measurable returns for Canada.

The Canadian Association of Social Workers is engaging Parliamentarians and the Government to support their profession through public safety, mental health and primary care policies.

Promoting health data interoperability, as critical to healthcare systems, ensuring medical professionals have access to the right information at the right time when providing care and improving patient outcomes. Anything related to opportunities to expand on or discuss current policies that relate to the need for physically, psychologically, and culturally safe environments for providers and learners. Supporting an increase awareness for digital and virtual health services.

The impact that food insecurity is having on the health of Canadians and what policies or programs the government should implement to help address this issue Support for the National School Food Program and any outcomes or input from the profession that may be requested or required. The impact of the health human resource crisis on the profession of dietitians including team based care programs and policy.

Educate decision-makers on Medline’s increased footprint across Canada, including domestic manufacturing and supply of medical supplies and devices (i.e. gloves, masks, gowns etc.) post-COVID-19 pandemic. Educate decision-makers on current medical supply and device procurement in Canada and advocate for an evaluation by Health Emergency Readiness Canada and other partner departments and agencies of the current federal procurement model to ensure Canada is maximizing value and efficiency on the procurement of medical supplies and devices.

Supporting Parkinson Awareness Month which calls for equitable, coordinated, and continuous Parkinson's care for everyone